Genetic manipulation of hematopoietic stem cells

Area of Science:

• * Hematopoietic stem cell (HSC) biology
• * Gene therapy vector development
• * Translational medicine

Background:

• * Gene transfer into HSCs has advanced stem cell research and offers therapeutic potential for genetic disorders.
• * Early retroviral vectors showed limitations in large mammals and human trials, with poor correlation between preclinical assays and clinical outcomes.
• * Development of superior preclinical models and a deeper understanding of HSC and vector biology were crucial.

Purpose of the Study:

• * To review the evolution of gene transfer into HSCs over the past two decades.
• * To highlight the development of improved preclinical assays and strategies for enhancing gene transfer efficiency.
• * To underscore the clinical benefits achieved through genetic manipulation of HSCs.

Main Methods:

• * Review of advancements in gene transfer technologies for HSCs.
• * Discussion of preclinical models, including xenogeneic and large animal transplantation systems.
• * Examination of strategies to improve gene transfer efficiency, such as vector optimization and adjunct therapies.

Main Results:

• * Early retroviral vectors had limited success in human HSC gene transfer, with in vitro assays poorly predicting in vivo outcomes.
• * Development of more relevant preclinical models and improved understanding of HSC biology have driven progress.
• * Novel strategies, including advanced vectors, cytokine combinations, and fibronectin fragments, have significantly enhanced gene transfer efficiency.

Conclusions:

• * Significant progress has been made in gene transfer into HSCs, moving from limited success to demonstrable clinical benefits.
• * Improved preclinical models and a better understanding of stem cell and vector biology are key to successful gene therapy.
• * Current strategies offer promising avenues for treating inherited and acquired disorders through HSC genetic manipulation.